Display options
Cite
Camuzard O, Trojani MC, Santucci-Darmanin S, et al. Autophagy in Osteosarcoma Cancer Stem Cells Is  Critical Process which Can Be Targeted by the Antipsychotic Drug Thioridazine. Cancers (Basel). 2020;12(12)doi: 10.3390/cancers12123675.
Camuzard, O., Trojani, M. C., Santucci-Darmanin, S., Pagnotta, S., Breuil, V., Carle, G. F., & Pierrefite-Carle, V. (2020). Autophagy in Osteosarcoma Cancer Stem Cells Is  Critical Process which Can Be Targeted by the Antipsychotic Drug Thioridazine. Cancers, 12(12), . https://doi.org/10.3390/cancers12123675
Camuzard, Olivier, et al. "Autophagy in Osteosarcoma Cancer Stem Cells Is  Critical Process which Can Be Targeted by the Antipsychotic Drug Thioridazine." Cancers vol. 12,12 (2020). doi: https://doi.org/10.3390/cancers12123675
Camuzard O, Trojani MC, Santucci-Darmanin S, Pagnotta S, Breuil V, Carle GF, Pierrefite-Carle V. Autophagy in Osteosarcoma Cancer Stem Cells Is  Critical Process which Can Be Targeted by the Antipsychotic Drug Thioridazine. Cancers (Basel). 2020 Dec 07;12(12). doi: 10.3390/cancers12123675. PMID: 33297525; PMCID: PMC7762415.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Dec 07;12(12). doi: 10.3390/cancers12123675.

Autophagy in Osteosarcoma Cancer Stem Cells Is  Critical Process which Can Be Targeted by the Antipsychotic Drug Thioridazine.

Cancers

Olivier Camuzard, Marie-Charlotte Trojani, Sabine Santucci-Darmanin, Sophie Pagnotta, Véronique Breuil, Georges F Carle, Valérie Pierrefite-Carle

Affiliations

  1. Faculté de Médecine Nice, Université Côte d'Azur, UMR E-4320 TIRO-MATOs CEA/DRF/Institut Joliot, CEDEX 2, 06107 Nice, France.
  2. Service de Chirurgie Réparatrice et de la Main, CHU de Nice, 06001 Nice cedex 1, France.
  3. Service de Rhumatologie, CHU de Nice, 06001 Nice, France.
  4. Centre Commun de Microscopie Appliquée, Université Côte d'Azur, 06107 Nice, France.

PMID: 33297525 PMCID: PMC7762415 DOI: 10.3390/cancers12123675

Abstract

Cancer stem cells (CSCs) represent a minor population of cancer cells with stem cell-like properties which are able to fuel tumor growth and resist conventional treatments. Autophagy has been described to be upregulated in some CSCs and to play a crucial role by maintaining stem features and promoting resistance to both hostile microenvironments and treatments. Osteosarcoma (OS) is an aggressive bone cancer which mainly affects children and adolescents and autophagy in OS CSCs has been poorly studied. However, this is a very interesting case because autophagy is often deregulated in this cancer. In the present work, we used two OS cell lines showing different autophagy capacities to isolate CSC-enriched populations and to analyze the autophagy in basal and nutrient-deprived conditions. Our results indicate that autophagy is more efficient in CSCs populations compared to the parental cell lines, suggesting that autophagy is a critical process in OS CSCs. We also showed that the antipsychotic drug thioridazine is able to stimulate, and then impair autophagy in both CSC-enriched populations, leading to autosis, a cell death mediated by the Na+/K

Keywords: Na+/K+ ATPase; autophagy; autosis; cancer stem cells; osteosarcoma

References

  1. J Clin Oncol. 1998 Nov;16(11):3641-8 - PubMed
  2. Int J Mol Sci. 2019 Jan 22;20(3): - PubMed
  3. Int J Cancer. 2019 Apr 1;144(7):1735-1745 - PubMed
  4. Cancer Res. 2009 Jul 15;69(14):5648-55 - PubMed
  5. Cell Death Differ. 2019 Mar;26(4):640-652 - PubMed
  6. Cancer Lett. 2016 Jan 28;370(2):286-95 - PubMed
  7. Autophagy. 2020 Aug 14;:1-20 - PubMed
  8. Cell Death Dis. 2015 May 07;6:e1753 - PubMed
  9. Cancer Lett. 2018 Oct 1;433:53-64 - PubMed
  10. Biomed Pharmacother. 2018 Jan;97:833-837 - PubMed
  11. J Biomed Sci. 2016 Nov 18;23(1):82 - PubMed
  12. Bone. 2014 May;62:56-63 - PubMed
  13. Cell Cycle. 2011 Nov 15;10(22):3871-85 - PubMed
  14. J Bone Oncol. 2019 Apr 03;16:100235 - PubMed
  15. Int J Cancer. 1977 Apr 15;19(4):505-10 - PubMed
  16. Cell. 2011 Nov 11;147(4):728-41 - PubMed
  17. FEBS J. 2014 Nov;281(21):4779-91 - PubMed
  18. Nat Rev Cancer. 2014 Nov;14(11):722-35 - PubMed
  19. J Immunol. 2017 Feb 15;198(4):1423-1428 - PubMed
  20. J Clin Invest. 2020 Jun 1;130(6):2978-2991 - PubMed
  21. Autophagy. 2016;12(1):1-222 - PubMed
  22. BMC Cancer. 2012 Apr 04;12:139 - PubMed
  23. Cell. 2012 Jun 8;149(6):1284-97 - PubMed
  24. Stem Cells Int. 2016;2016:3631764 - PubMed
  25. JACC Basic Transl Sci. 2020 Aug 24;5(8):857-869 - PubMed
  26. Oncol Rep. 2016 Sep;36(3):1219-25 - PubMed
  27. Autophagy. 2017 Feb;13(2):264-284 - PubMed
  28. Oncol Lett. 2017 Dec;14(6):8171-8177 - PubMed
  29. Oncotarget. 2016 Aug 2;7(31):50805-50813 - PubMed
  30. Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20364-71 - PubMed
  31. PLoS One. 2013;8(2):e57172 - PubMed
  32. Biomed Pharmacother. 2018 Oct;106:200-209 - PubMed
  33. JCI Insight. 2020 Jan 16;5(1): - PubMed
  34. J Clin Invest. 2020 Aug 3;130(8):4006-4018 - PubMed
  35. Nat Rev Cancer. 2012 Apr 26;12(6):401-10 - PubMed
  36. Cancer Res. 1983 Sep;43(9):4308-14 - PubMed
  37. Oncogene. 2013 May 2;32(18):2261-72, 2272e.1-11 - PubMed
  38. J Exp Clin Cancer Res. 2017 Nov 29;36(1):171 - PubMed
  39. Cancer Lett. 2016 Jan 28;370(2):268-74 - PubMed
  40. Cell Death Differ. 2015 Mar;22(3):367-76 - PubMed
  41. Neoplasia. 2005 Nov;7(11):967-76 - PubMed

Publication Types

Grant support